Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 1/9/2026 | Buy | Roth Capital | |
| 10/6/2025 | $27.00 | Buy | Stifel |
| 10/6/2025 | $78.00 | Overweight | Piper Sandler |
| 10/6/2025 | $34.00 | Outperform | Leerink Partners |
4 - LB PHARMACEUTICALS INC (0001691082) (Issuer)
4 - LB PHARMACEUTICALS INC (0001691082) (Issuer)
3 - LB PHARMACEUTICALS INC (0001691082) (Issuer)
4 - LB PHARMACEUTICALS INC (0001691082) (Issuer)
4 - LB PHARMACEUTICALS INC (0001691082) (Issuer)
4 - LB PHARMACEUTICALS INC (0001691082) (Issuer)
Roth Capital initiated coverage of LB Pharmaceuticals with a rating of Buy
Stifel initiated coverage of LB Pharmaceuticals with a rating of Buy and set a new price target of $27.00
Piper Sandler initiated coverage of LB Pharmaceuticals with a rating of Overweight and set a new price target of $78.00
Issued on behalf of Helus PharmaVANCOUVER, BC, Feb. 27, 2026 /CNW/ -- Equity-Insider.com News Commentary -- Psychedelic compounds are edging closer to regulatory approval as pivotal trials in treatment-resistant depression and anxiety advance through late-stage development[1]. The sector is shedding its countercultural reputation as biotech firms reposition serotonergic and psychedelic-derived therapies as mainstream pharmaceutical candidates[2]. Five companies are building the clinical programs to get there: Helus Pharma (NASDAQ:HELP), AtaiBeckley (NASDAQ:ATAI), Definium Therapeutics (NASDAQ:DFTX), GH Research (NASDAQ:GHRS), and LB Pharmaceuticals (NASDAQ:LBRX).
NEW YORK, Feb. 10, 2026 (GLOBE NEWSWIRE) -- LB Pharmaceuticals Inc ("LB Pharmaceuticals" or the "Company") (NASDAQ:LBRX) today announced that it has granted to Dr. Minako Pazdera, the new General Counsel of LB Pharmaceuticals, an equity award outside of, but subject to the terms and conditions of, the LB Pharmaceuticals Inc 2025 Equity Incentive Plan. The equity award was granted on February 10, 2026, pursuant to the "inducement grant" exception provided under Nasdaq Listing Rule 5635(c)(4) as an inducement material to Dr. Pazdera entering into employment with LB Pharmaceuticals. Dr. Pazdera received options to purchase 140,000 shares of LB Pharmaceuticals' common stock. The options carry
NEW YORK, Feb. 05, 2026 (GLOBE NEWSWIRE) -- LB Pharmaceuticals Inc ("LB Pharmaceuticals" or the "Company") (NASDAQ:LBRX), a late-stage biopharmaceutical company developing novel therapies for schizophrenia, bipolar depression, and other neuropsychiatric diseases, today announced that it has entered into a securities purchase agreement to sell 3,306,571 shares of its common stock and pre-funded warrants to purchase up to 1,417,107 shares of its common stock to a select group of institutional investors in a private placement. The purchase price of each share of common stock is $21.17. The purchase price of each pre-funded warrant is $21.1699, which represents the per share purchase price for
SCHEDULE 13G/A - LB PHARMACEUTICALS INC (0001691082) (Subject)
8-K - LB PHARMACEUTICALS INC (0001691082) (Filer)
SCHEDULE 13G - LB PHARMACEUTICALS INC (0001691082) (Subject)
NEW YORK, Jan. 21, 2026 (GLOBE NEWSWIRE) -- LB Pharmaceuticals, Inc ("LB Pharmaceuticals" or the "Company") (NASDAQ:LBRX), a clinical-stage biopharmaceutical company developing novel therapies for schizophrenia, bipolar depression, and other neuropsychiatric diseases, today announced the appointment Dr. Minako Pazdera as General Counsel. Dr. Pazdera joins LB Pharmaceuticals with more than 25 years of experience spanning corporate governance, intellectual property, strategic corporate transactions and compliance. "We are delighted to welcome Minako to LB Pharmaceuticals," said Heather Turner, Chief Executive Officer. "Dr. Pazdera has broad expertise encompassing both financial and strateg
NEW YORK, Jan. 06, 2026 (GLOBE NEWSWIRE) -- LB Pharmaceuticals, Inc ("LB Pharmaceuticals" or the "Company") (NASDAQ:LBRX), a clinical-stage biopharmaceutical company developing novel therapies for schizophrenia, bipolar depression, and other neuropsychiatric diseases, today announced the appointments of Ellen Rose as Senior Vice President, Corporate Affairs and Lindsay Beaupre as Senior Vice President, People and Culture. "We are pleased to welcome Ellen and Lindsay to LB Pharmaceuticals," said Heather Turner, Chief Executive Officer. "Ms. Rose has extensive experience in corporate communications, investor relations, and patient advocacy within the biopharma industry. Ms. Beaupre is a sea
NEW YORK, Nov. 12, 2025 (GLOBE NEWSWIRE) -- LB Pharmaceuticals, Inc ("LB Pharmaceuticals" or the "Company") (NASDAQ:LBRX), a clinical-stage biopharmaceutical company developing novel therapies for schizophrenia, bipolar depression, and other neuropsychiatric diseases, today announced the appointment of Kaya Pai Panandiker as Chief Commercial Officer. Ms. Pai Panandiker is a seasoned commercial and operating leader with more than 20 years of global biopharmaceutical experience, including extensive leadership in neuroscience commercialization and in launching and scaling global brands. "We are very pleased to welcome Kaya to LB Pharmaceuticals," said Heather Turner, Chief Executive Officer